SYROS PHARMACEUTICALS INC's ticker is SYRS and the CUSIP is 87184Q107. A total of 102 filers reported holding SYROS PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is 0.76 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2021 | $73,375 | -8.9% | 16,415 | +52.5% | 0.00% | 0.0% |
| Q1 2021 | $80,515 | -40.7% | 10,764 | -13.9% | 0.00% | -50.0% |
| Q4 2020 | $135,679 | +22.7% | 12,505 | 0.0% | 0.00% | 0.0% |
| Q3 2020 | $110,544 | -17.1% | 12,505 | 0.0% | 0.00% | 0.0% |
| Q2 2020 | $133,303 | +83.9% | 12,505 | +2.3% | 0.00% | 0.0% |
| Q1 2020 | $72,494 | -47.4% | 12,225 | -8.0% | 0.00% | 0.0% |
| Q3 2019 | $137,940 | +414.0% | 13,289 | +358.6% | 0.00% | – |
| Q2 2019 | $26,835 | -75.7% | 2,898 | -68.7% | 0.00% | -100.0% |
| Q3 2018 | $110,251 | -99.9% | 9,257 | 0.0% | 0.00% | 0.0% |
| Q2 2018 | $94,514,000 | +60485.9% | 9,257 | -4.5% | 0.00% | +100.0% |
| Q2 2017 | $156,000 | – | 9,696 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ally Bridge Group (NY) LLC | 3,139,895 | $23,486,000 | 4.50% |
| Samsara BioCapital, LLC | 2,189,199 | $14,769,000 | 2.72% |
| Bain Capital Life Sciences Investors, LLC | 5,785,036 | $43,272,000 | 2.45% |
| Omega Fund Management, LLC | 1,562,500 | $11,688,000 | 1.11% |
| Flagship Pioneering Inc. | 2,938,494 | $21,980,000 | 0.35% |
| EcoR1 Capital, LLC | 1,000,000 | $7,480,000 | 0.33% |
| Altium Capital Management LP | 126,702 | $948,000 | 0.26% |
| Nikko Asset Management Americas, Inc. | 5,042,009 | $37,714,000 | 0.18% |
| Artal Group S.A. | 1,025,000 | $7,667,000 | 0.14% |
| Orbimed Advisors | 1,837,500 | $13,745,000 | 0.13% |